Skip to content
Study details
Enrolling now

A Study on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for Paroxysmal Atrial Fibrillation

Biosense Webster, Inc.
NCT IDNCT06455098ClinicalTrials.gov data as of Apr 2026
Target enrollment

440

Study length

about 2 years

Ages

18–80

Locations

43 sites in AZ, CA, CO +17

What this study is about

Researchers are testing the safety and effectiveness of a device called OMNYPULSE™ to treat paroxysmal atrial fibrillation (PAF), an irregular heart rate. The trial will last 732 days and involve approximately 440 participants.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Use OMNYPULSE™ Catheter with the TRUPULSE Generator

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Number of Participants with Primary Adverse Events (PAEs)

Secondary: Change from Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score

Devices

therapeutic, implantable

Body systems

Cardiology / Heart